Edwards Lifesciences
EW
$84.24
-1.80%
Edwards Lifesciences designs, manufactures, and markets medical devices for advanced structural heart disease, with a portfolio spanning surgical tissue heart valves, transcatheter aortic valve replacement (TAVR), and transcatheter mitral and tricuspid therapies; roughly 60% of sales come from outside the US. Spun off from Baxter International in 2000, the firm has established itself as the undisputed market leader in transcatheter heart valve technology, a position built on decades of clinical evidence and a deep pipeline of minimally invasive structural heart innovations. The current investor narrative centers on a beat-and-raise Q2 2026 quarter (revenue up 13.6% year over year to $1.74 billion) and a proposed US agency expansion of Medicare coverage for TAVR procedures, which analysts view as a significant positive catalyst for the market leader. Offsetting this optimism is a sharp stock pullback since mid-summer, with the shares down roughly 6% over the past month and underperforming the S&P 500 by more than 13 percentage points over three months, as investors debate whether the TAVR growth runway is fully priced and whether transcatheter mitral and tricuspid (TMTT) investments will translate into durable revenue. The debate now hinges on whether procedural volume acceleration and TMTT commercialization can re-ignite a stock that has stalled despite solid fundamental execution.…
EW
Edwards Lifesciences
$84.24
Related headlines
Investment Opinion: Should I buy EW Today?
Based on the synthesis of fundamental, valuation, and analyst data, the recommendation for Edwards Lifesciences is a Hold. The company is a high-quality market leader with strong revenue growth of 13.6% and exceptional gross margins of 77.6%, but the stock's premium valuation at 46.33x trailing earnings and recent negative momentum suggest limited near-term upside. The analyst consensus is 'buy' with an average target of $100.96, implying 18.6% upside, but the wide target range and the fact that the low target sits at the current price indicate uncertainty. A Hold rating reflects a balanced view: the fundamentals are solid, but the valuation already prices in significant growth, and the stock lacks a clear catalyst in the immediate term.
Supporting evidence for the Hold includes the forward PE of 25.21x, which is more reasonable and closer to sector norms, suggesting the premium is largely due to depressed trailing earnings. Revenue growth of 13.63% year over year is healthy, and free cash flow of $1.434 billion is robust, providing financial flexibility. However, the PS ratio of 8.22x is well above the industry average of 4-6x, and the PB ratio of 4.82x is near the low end of its historical range, which could signal relative value but also reflects the market's de-rating. The net margin of 13.89% in Q2 2026 was compressed by a tax rate spike, but gross margin stability in the 77.6%-78.3% range demonstrates pricing power. Overall, the valuation is not cheap, but the forward multiple and depressed PB suggest the stock is fairly valued relative to its growth prospects.
The biggest risks that could invalidate the Hold thesis include a failure to expand Medicare coverage for TAVR, which would remove a key catalyst, and increased competition in the TAVR space that could pressure pricing and market share. Additionally, if revenue growth decelerates below 10%, the premium multiple could compress significantly. The rating would upgrade to Buy if the stock pulls back to the 52-week low of $72.30, offering a more attractive entry point, or if TAVR expansion is confirmed and TMTT revenues accelerate. Conversely, a downgrade to Sell would occur if revenue growth falls below 8% or if gross margins decline below 75%. Relative to its history and peers, EW appears fairly valued on a forward basis but overvalued on trailing metrics, warranting a Hold until clearer catalysts emerge.
Sign up to view all
EW 12-Month Price Forecast
Edwards Lifesciences presents a balanced risk-reward profile. The company's strong fundamentals, including 13.6% revenue growth, 77.6% gross margins, and a pristine balance sheet, support a bullish long-term view. However, the premium valuation and recent negative momentum warrant caution. The Medicare TAVR expansion is a potential catalyst, but its timing and impact are uncertain. Analyst sentiment is bullish, but the wide target range reflects divergent views. I would upgrade to bullish if the stock breaks above $96.29 (52-week high) on strong volume or if Medicare expansion is confirmed. I would downgrade to bearish if revenue growth decelerates below 10% or if gross margins fall below 75%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Edwards Lifesciences's 12-month outlook, with a consensus price target around $101.96 and implied upside of +21.0% versus the current price.
Average Target
$101.96
0 analysts
Implied Upside
+21.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$84 - $110
Analyst target range
Coverage is robust with 26 analysts, and sentiment is decidedly bullish: the consensus recommendation is "buy" with a recommendation mean of 1.62 (where 1 is strong buy and 5 is strong sell), and the average target price is $100.96. Against the current price of $85.15, that implies upside of approximately 18.6%, a meaningful gap that suggests the sell-side views the recent pullback as a buying opportunity rather than a fundamental deterioration. The consensus leans clearly bullish, with the vast majority of recent ratings in the Buy/Outperform/Overweight camp, and the estimated average EPS of $4.62 for the forward period supports the constructive stance. The target range spans $84.00 to $110.00, a spread of $26, or roughly 31% of the low target, which signals moderate-to-high uncertainty rather than strong conviction. The high target of $110 implies roughly 29% upside and likely assumes successful Medicare TAVR expansion, accelerating TMTT revenue, and multiple expansion back toward historical highs; the low target of $84 is essentially at the current price and prices in flat procedural growth, margin pressure from R&D investment, and no re-rating. Recent institutional actions are mixed but mostly supportive: Leerink Partners upgraded to Outperform from Market Perform on July 24, 2026, while BTIG, Piper Sandler, JP Morgan, Mizuho, RBC, Citigroup, and Evercore ISI all maintained bullish ratings; Truist is the notable holdout with a Hold rating. The absence of any Sell ratings and the clustering of targets above $100 suggest the Street sees the current weakness as temporary, though the wide range and the fact that the low target sits at the current price mean downside protection is limited if execution disappoints.
Bulls vs Bears: EW Investment Factors
The bull case for Edwards Lifesciences rests on its dominant TAVR position, strong revenue growth of 13.6%, exceptional profitability with gross margins above 77%, and a pristine balance sheet with minimal debt. The proposed Medicare coverage expansion for TAVR procedures provides a significant catalyst, and analyst consensus is bullish with an average target of $100.96, implying 18.6% upside. However, the bear case highlights the stock's premium valuation at 46.33x trailing earnings, concentration risk in TAVR, recent negative momentum with underperformance versus the S&P 500, and earnings volatility due to tax rate fluctuations. Currently, the bear evidence appears slightly stronger given the stock's recent underperformance and premium valuation, but the bull case is supported by solid fundamentals and a clear catalyst. The single most important tension is whether the Medicare TAVR expansion will materialize and drive procedural volume acceleration; if it does, the stock could re-rate higher, but if it stalls, the premium multiple may compress further.
Bullish
- TAVR Medicare Expansion Catalyst: A U.S. agency proposal to expand and simplify Medicare coverage for TAVR procedures is a significant positive catalyst for Edwards Lifesciences, the market leader in transcatheter heart valves. This regulatory tailwind could accelerate procedural volumes and expand the addressable patient population, directly benefiting EW's largest segment, TAVR, which generated $1.258 billion in Q2 2026 revenue.
- Strong Revenue Growth and Beat-and-Raise: Q2 2026 revenue rose 13.63% year over year to $1.741 billion, with sequential growth from $1.649 billion in Q1 2026. The company delivered a beat-and-raise quarter, showcasing robust demand for its heart valve therapies, and the positive momentum supports the premium valuation.
- Exceptional Profitability and Balance Sheet: Gross margin stands at 77.56% in Q2 2026, with operating margin of 29.84% and net margin of 13.89%. The balance sheet is pristine with debt-to-equity of just 0.068, current ratio of 3.72, and cash per share of $7.38, providing ample flexibility for R&D and strategic investments.
- Robust Free Cash Flow Generation: Trailing free cash flow is $1.434 billion, with Q2 2026 free cash flow of $585 million and operating cash flow of $651.9 million, easily covering capital expenditures of $66.9 million. This strong cash generation funds internal growth initiatives without reliance on external financing.
Bearish
- Premium Valuation Leaves Little Room for Error: The trailing PE of 46.33x and PS ratio of 8.22x represent a significant premium to the medical devices sector average of 20-25x earnings and 4-6x sales. This premium is justified by high margins and growth, but it prices in substantial execution, making the stock vulnerable to any deceleration.
- TAVR Concentration Risk: TAVR revenue of $1.258 billion dwarfs TMTT at $198.6 million and Surgical at $284.1 million, meaning the company is highly levered to a single franchise. Any competitive or reimbursement shock to TAVR would disproportionately impact the entire investment thesis.
- Recent Underperformance and Negative Momentum: EW is down 6.24% over one month and 9.77% over three months, underperforming SPY by 6.83 and 13.11 percentage points, respectively. The stock sits at $85.15, only 58.9% of its 52-week range, and below its 50-day trend, indicating weakening short-term momentum.
- Earnings Volatility and Tax Rate Spike: Net margin swung from 23.09% in Q1 2026 to 13.89% in Q2 2026, largely due to a spike in the effective tax rate to 53.56% from 17.06%. This volatility, despite higher revenue, highlights earnings unpredictability and potential margin pressure.
EW Technical Analysis
EW is in a broad recovery trend that has lost steam: the stock is up 11.09% over the past year but sits at $85.15, only about 58.9% of its 52-week range of $72.30 to $96.29, meaning it is trading in the middle of its annual band rather than near highs. After peaking at $95.18 on July 6, 2026, the shares have given back roughly 10.5% and are now below their 50-day trend, suggesting the year-long advance is consolidating rather than accelerating. The mid-range positioning is ambiguous: it is neither an overextended momentum name nor a deeply discounted falling knife, which argues for patience until a directional resolution. Recent momentum is clearly negative and diverging from the longer-term uptrend: EW is down 6.24% over one month and 9.77% over three months, versus a 1-year gain of 11.09%, and it has underperformed SPY by 6.83 percentage points over one month and 13.11 points over three months. The 6-month change of +5.06% versus the 3-month change of -9.77% shows that most of the past half-year's gains were earned in the spring and have since been surrendered, a classic deceleration pattern. With no RSI provided, the price action itself implies weakening short-term momentum, and the 3.2 short ratio indicates bears are not aggressively pressing, but the absence of a volume surge on the decline suggests selling is orderly rather than panic-driven. Key levels are well defined: support sits at the 52-week low of $72.30, roughly 15.1% below the current $85.15, while resistance is the 52-week high of $96.29, about 13.1% above. A breakout above $96.29 would confirm a resumption of the primary uptrend and likely draw momentum buyers, whereas a breakdown below $72.30 would signal a full trend reversal and expose the stock to deeper losses. With a beta of 0.852, EW is roughly 15% less volatile than the S&P 500, which supports smaller position-sizing adjustments and makes the 13.19% maximum drawdown relatively contained for a single-name healthcare device stock; the low beta also means the stock will likely lag a broad market rally unless company-specific catalysts emerge.
Beta
0.86
0.86x market volatility
Max Drawdown
-13.2%
Largest decline past year
52-Week Range
$72-$96
Price range past year
Annual Return
+11.2%
Cumulative gain past year
| Period | EW Return | S&P 500 |
|---|---|---|
| 1m | -2.9% | +1.0% |
| 3m | -8.6% | +2.5% |
| 6m | +8.2% | +13.9% |
| 1y | +11.2% | +15.0% |
| ytd | -1.3% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EW Fundamental Analysis
Revenue is growing at a healthy clip: Q2 2026 revenue of $1.741 billion rose 13.63% year over year from $1.532 billion in Q2 2025, and the sequential progression from $1.649 billion in Q1 2026 confirms positive momentum. Segment data shows the growth engine is TAVR at $1.258 billion, dwarfing TMTT at $198.6 million and Surgical at $284.1 million, so the company remains highly levered to a single franchise. The multi-quarter trend is constructive but uneven: revenue climbed from $1.553 billion in Q3 2025 to $1.569 billion in Q4 2025, $1.649 billion in Q1 2026, and $1.741 billion in Q2 2026, with the Q4 2025 softness (net income of just $91.2 million) reflecting one-time items rather than demand weakness. For the investment case, the 13.6% top-line growth supports the premium multiple, but the concentration in TAVR means any competitive or reimbursement shock would hit the entire thesis. Profitability is strong and improving: Q2 2026 net income was $241.9 million on a 13.89% net margin, while gross margin was 77.56% and operating margin 29.84%, both healthy for medical devices. However, the quarterly net margin has been volatile, swinging from 23.09% in Q1 2026 to 13.89% in Q2 2026, largely due to a spike in the effective tax rate to 53.56% in Q2 from 17.06% in Q1, which compressed net income despite higher revenue. Gross margin has been remarkably stable in the 77.6%-78.3% range across the last four quarters, indicating pricing power and manufacturing efficiency, and the 26.97% trailing operating margin is consistent with a high-quality device franchise. The balance sheet is exceptionally clean: debt-to-equity is just 0.068, the current ratio is 3.72, and cash per share is $7.38, giving the company ample liquidity. Free cash flow is robust at $1.434 billion on a trailing basis, with Q2 2026 free cash flow of $585 million and operating cash flow of $651.9 million, easily covering $66.9 million of capital expenditure. ROE of 10.38% and ROA of 8.37% are respectable but not spectacular, reflecting the large cash pile and heavy reinvestment in R&D ($278.9 million in Q2 2026); the company funds growth internally with no dividend and only modest buybacks ($53.3 million in Q2 2026), so financial risk is low.
Quarterly Revenue
$1.7B
2026-06
Revenue YoY Growth
+13.6%
YoY Comparison
Gross Margin
77.6%
Latest Quarter
Free Cash Flow
$1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EW Overvalued?
Because EW is profitable with positive net income of $241.9 million in Q2 2026, the PE ratio is the primary metric: the trailing PE is 46.33x versus a forward PE of 25.21x, a dramatic 45.6% compression that implies the market expects earnings to roughly double. That gap is the crux of the valuation debate, as it prices in substantial EPS growth (consensus 2027 EPS of $4.62 versus trailing EPS of $0.02, which is distorted by one-time items) and leaves little room for execution missteps. On a price-to-sales basis, EW trades at 8.22x, with EV/Sales of 7.01x and EV/EBITDA of 33.31x, all rich absolute multiples. Relative to the medical devices sector, EW's 46.33x trailing PE and 8.22x PS represent a premium to the broader industry average (typically 20-25x earnings and 4-6x sales), a spread of roughly 85-130% on PE and 40-100% on PS. That premium is justified by EW's 77.6% gross margin, 13.6% revenue growth, and dominant TAVR position, but it also means the stock is priced for perfection and vulnerable to any deceleration. The forward PE of 25.21x is far more reasonable and closer to sector norms, suggesting the premium is largely a function of depressed trailing earnings rather than an inherently expensive forward valuation. Historically, EW's PE has ranged from about 27x to 60x over the past several years, with the current 46.33x sitting in the upper-middle of that band, while the PS ratio of 8.22x is well below the 29-60x range seen in 2021-2024 (though those figures reflect different share counts and accounting). The PB ratio of 4.82x is near the low end of its historical 4.1x-13.9x range, which could signal relative value on a book basis. Overall, the valuation is not cheap, but the forward earnings multiple and depressed PB suggest the market has already de-rated the stock meaningfully from its pandemic-era peak, leaving room for re-rating if TAVR expansion and TMTT commercialization deliver.
PE
46.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 27x~60x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks for Edwards Lifesciences are relatively low given its strong balance sheet, but several factors warrant attention. The company's debt-to-equity ratio is just 0.068, and it holds $7.38 in cash per share, providing a substantial cushion. However, revenue is highly concentrated in TAVR, which accounted for $1.258 billion of the $1.741 billion in Q2 2026 revenue, meaning any competitive threat or reimbursement change could severely impact results. Additionally, earnings volatility is evident: net margin dropped from 23.09% in Q1 2026 to 13.89% in Q2 2026 due to a spike in the effective tax rate to 53.56%, highlighting potential unpredictability in profitability. The company's heavy reinvestment in R&D ($278.9 million in Q2 2026) is necessary to maintain leadership but pressures near-term margins.
Market and competitive risks are significant given EW's premium valuation and recent underperformance. The stock trades at a trailing PE of 46.33x and PS of 8.22x, well above the medical devices sector average of 20-25x earnings and 4-6x sales, leaving it vulnerable to valuation compression if growth decelerates. The beta of 0.852 indicates the stock is about 15% less volatile than the S&P 500, but it has underperformed the index by 13.11 percentage points over three months, suggesting sector rotation or company-specific concerns. Competitive threats in the TAVR space are intensifying, and any loss of market share could undermine the premium multiple. Regulatory headwinds, such as potential changes to Medicare reimbursement, also pose risks, although the current proposal is favorable.
In a worst-case scenario, a combination of TAVR market share loss, failure to gain Medicare expansion, and margin compression from increased competition could drive the stock down to its 52-week low of $72.30, representing a decline of approximately 15.1% from the current price of $85.15. If the bear case fully materializes, including a breakdown below technical support and analyst downgrades, the stock could test the low end of the analyst target range at $84, but a more severe scenario might see it fall to the 52-week low. The maximum drawdown over the past year was 13.19%, but in a prolonged downturn, losses could exceed 20% from current levels. Investors should be prepared for potential downside to $72-$75, a decline of 12-15%, if execution disappoints and the premium multiple contracts.
FAQ
The key risks for EW include: 1) Concentration risk: TAVR accounts for $1.258 billion of $1.741 billion in Q2 2026 revenue, so any competitive or reimbursement shock to this franchise would be severe. 2) Valuation risk: The trailing PE of 46.33x leaves little room for error; a growth slowdown could trigger multiple compression. 3) Regulatory risk: The proposed Medicare expansion may not be finalized or could be less favorable than expected. 4) Earnings volatility: Net margin swung from 23.09% in Q1 2026 to 13.89% in Q2 2026 due to a tax rate spike, highlighting unpredictability. These risks are ranked from highest to lowest severity, with concentration and valuation being the most critical.
The 12-month forecast for EW includes three scenarios: bull case (30% probability) with a target range of $100-$110, base case (50% probability) with a target range of $95-$105, and bear case (20% probability) with a target range of $72-$84. The base case is most likely, assuming steady revenue growth of 12-14% and gradual Medicare expansion, leading the stock to trade around the analyst average target of $100.96. The bull case hinges on successful Medicare expansion and TMTT acceleration, while the bear case assumes delays and competitive pressures. The key assumption behind the base case is that TAVR growth remains robust and the company maintains its market leadership.
EW appears overvalued on trailing metrics but fairly valued on forward estimates. The trailing PE of 46.33x is well above the medical devices sector average of 20-25x, and the PS ratio of 8.22x exceeds the typical 4-6x range. However, the forward PE of 25.21x is more reasonable, suggesting the market expects earnings to roughly double, as indicated by the consensus 2027 EPS estimate of $4.62. The PB ratio of 4.82x is near the low end of its historical range, which could signal relative value. The market is pricing in significant growth from TAVR expansion and TMTT commercialization; if these fail to materialize, the stock could de-rate. Overall, the valuation is full but not unreasonable given the company's growth prospects and profitability.
EW is a good buy for long-term investors who believe in the structural heart market and are willing to pay a premium for a market leader. The stock trades at $85.15, with an analyst average target of $100.96, implying 18.6% upside. The company's strong fundamentals, including 13.6% revenue growth and 77.6% gross margins, support the bull case. However, the trailing PE of 46.33x is rich, and the stock has underperformed the S&P 500 by 13.11 percentage points over three months, indicating near-term headwinds. The biggest downside risk is a failure to expand Medicare coverage for TAVR, which could lead to a drop to the 52-week low of $72.30, a 15% decline. For risk-averse investors, waiting for a pullback to the low $80s or a confirmed catalyst would be prudent.
EW is more suitable for long-term investment given its strong fundamentals, low beta of 0.852, and no dividend, which suggests it is a growth-oriented stock. The company's leadership in TAVR and pipeline in TMTT offer multi-year growth potential, but near-term volatility and premium valuation make it less ideal for short-term trading. The stock has a 1-year return of 11.09% but has underperformed the S&P 500 by 3.92 percentage points, indicating that timing is important. A suggested minimum holding period is 3-5 years to allow for the realization of Medicare expansion benefits and TMTT commercialization. Short-term traders might find opportunities around earnings or regulatory news, but the low beta and lack of dividend make it less attractive for income or momentum strategies.